Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 2/20 | 0.41 |
| ▸ | L3MBTL3 | Q96JM7 | 8/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 7/20 | 0.39 |
| ▸ | MBTD1 | Q05BQ5 | 6/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.39 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.38 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.38 |
| ▸ | MGLL | Q99685 | 3/20 | 0.36 |
| ▸ | TNKS | O95271 | 1/20 | 0.36 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2299298 | 1.00 | NAMPT (0.41) | NAMPTL3MBTL3L3MBTL1MBTD1LRRK2 | |
| SCHEMBL2296894 | 1.00 | NAMPT (0.41) | NAMPTL3MBTL3L3MBTL1MBTD1LRRK2 | |
| SCHEMBL2301303 | 0.93 | NAMPT (0.41) | NAMPTMGLLTNKSTNKS2 | |
| SCHEMBL2302392 | 0.93 | NAMPT (0.41) | NAMPTMGLLTNKSTNKS2 | |
| SCHEMBL2299295 | 0.91 | NAMPT (0.39) | NAMPTALKMGLLTNKSTNKS2 | |
| SCHEMBL12426044 | 0.91 | NAMPT (0.39) | NAMPTALKMGLLTNKSTNKS2 | |
| SCHEMBL13513555 | 0.88 | L3MBTL3 (0.39) | L3MBTL3L3MBTL1MBTD1LRRK2KDM4E | |
| SCHEMBL13513567 | 0.88 | NAMPT (0.38) | NAMPTLRRK2ALKMGLLTNKS | |
| SCHEMBL2296932 | 0.86 | SPR (0.37) | NAMPTL3MBTL3MBTD1ALDH1A1KMT2A | |
| SCHEMBL2297696 | 0.83 | TNKS (0.41) | TNKSTNKS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7994176-B2 | Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 | ELI LILLY AND COMPANY (US) | 2011-08-09 | — | — | US | claimed |
| EP-2021337-B1 | INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | LILLY CO ELI (US) | 2010-01-13 | — | — | EP | claimed |
| US-20090099182-A1 | INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | ELI LILLY AND COMPANY | 2009-04-16 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099182-A1 | INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | HSD11B1, HSD11B2, HSD3B1 | NAMPT 1816/4885L3MBTL3 4755/4885L3MBTL1 3444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.